Document Detail

RRP22: a novel neural tumor suppressor for astrocytoma.
MedLine Citation:
PMID:  21264544     Owner:  NLM     Status:  Publisher    
Astrocytomas are the most common neoplasm of the central nervous system. Although progress has been made, the survival rate of astrocytoma is still poor. Therefore, improving the prognosis of patients with astrocytomas relies on effective therapies that are directed against unique molecular aberrations. Previous studies have revealed that a novel member of the Ras superfamily, RRP22, which is located on chromosome 22 on the 12q site, is exclusively expressed in the central nervous system. RRP22 can be modified by farnesyl and down-regulated in a variety of neural tumor cell lines. In this study, we analyzed the mRNA level of RRP22 in normal brain tissues and astrocytomas using quantitative RT-PCR. Our results showed that the mRNA level in astrocytomas was significantly down-regulated compared to levels in normal tissues. As the pathological grade (World Health Organization (WHO) classification 2007) increased, the expression of RRP22 decreased. However, according to our research, there was no significant difference between malignant astrocytomas with pathological grades of III or IV. To investigate the possible effects of RRP22 on the biological behavior of glioma cells, we transfected RRP22 into a malignant cell line of astrocytomas, U251. We found that RRP22 inhibited growth, decreased invasiveness, and induced cell death. Thus, RRP22 is a special neural tumor suppressor for human astrocytomas, although further studies are needed to define the detailed mechanisms.
Ruokun Chen; Liang Yang; Jiasheng Fang; Lei Huo; Mingyu Zhang; Fenghua Chen; Jinfang Liu; Jun Wu; Yanjin Wang
Related Documents :
21685724 - Beclin 1 deficiency is associated with increased hypoxia-induced angiogenesis.
22186294 - A small interfering rna targeting nf-κb p65 alone or combined with 5-fu inhibits growt...
21748764 - Promotion of tumor cell metastasis and vasculogenic mimicry by way of transcription coa...
15010854 - A novel antimetabolite, tas-102 retains its effect on fu-related resistant cancer cells.
10052154 - Distribution and pharmacokinetics of photofrin in human bile duct cancer.
9393974 - Suppression of anchorage-independent growth and matrigel invasion and delayed tumor for...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-1-25
Journal Detail:
Title:  Medical oncology (Northwood, London, England)     Volume:  -     ISSN:  1559-131X     ISO Abbreviation:  -     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2011-1-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9435512     Medline TA:  Med Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Neurosurgery, Xiangya Hospital of Central South University, 410078, Changsha, Hunan, People's Republic of China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cyclin A and cyclin B1 overexpression in differentiated thyroid carcinoma.
Next Document:  Hyponatremia associated with Ipilimumab-induced hypophysitis.